title: Identification and biochemical characterization of small-molecule inhibitors of Clostridium botulinum neurotoxin serotype A.
abstract: An integrated strategy that combined in silico screening and tiered biochemical assays (enzymatic, in vitro, and ex vivo) was used to identify and characterize effective small-molecule inhibitors of Clostridium botulinum neurotoxin serotype A (BoNT/A). Virtual screening was initially performed by computationally docking compounds of the National Cancer Institute (NCI) database into the active site of BoNT/A light chain (LC). A total of 100 high-scoring compounds were evaluated in a high-performance liquid chromatography (HPLC)-based protease assay using recombinant full-length BoNT/A LC. Seven compounds that significantly inhibited the BoNT/A protease activity were selected. Database search queries of the best candidate hit [7-((4-nitro-anilino)(phenyl)methyl)-8-quinolinol (NSC 1010)] were performed to mine its nontoxic analogs. Fifty-five analogs of NSC 1010 were synthesized and examined by the HPLC-based assay. Of these, five quinolinol derivatives that potently inhibited both full-length BoNT/A LC and truncated BoNT/A LC (residues 1 to 425) were selected for further inhibition studies in neuroblastoma (N2a) cell-based and tissue-based mouse phrenic nerve hemidiaphragm assays. Consistent with enzymatic assays, in vitro and ex vivo studies revealed that these five quinolinol-based analogs effectively neutralized BoNT/A toxicity, with CB 7969312 exhibiting ex vivo protection at 0.5 microM. To date, this is the most potent BoNT/A small-molecule inhibitor that showed activity in an ex vivo assay. The reduced toxicity and high potency demonstrated by these five compounds at the biochemical, cellular, and tissue levels are distinctive among the BoNT/A small-molecule inhibitors reported thus far. This study demonstrates the utility of a multidisciplinary approach (in silico screening coupled with biochemical testing) for identifying promising small-molecule BoNT/A inhibitors.
authors.affiliation: Integrated Toxicology Division, U.S. Army Medical Research Institute of Infectious Diseases, 1425 Porter St., Fort Detrick, MD 21702, USA.
authors.forename: Virginia
authors.initials: V
authors.lastname: Roxas-Duncan
authors.forename: Istvan
authors.initials: I
authors.lastname: Enyedy
authors.forename: Vicki A
authors.initials: VA
authors.lastname: Montgomery
authors.forename: Vanessa S
authors.initials: VS
authors.lastname: Eccard
authors.forename: Marco A
authors.initials: MA
authors.lastname: Carrington
authors.forename: Huiguo
authors.initials: H
authors.lastname: Lai
authors.forename: Nizamettin
authors.initials: N
authors.lastname: Gul
authors.forename: David C H
authors.initials: DC
authors.lastname: Yang
authors.forename: Leonard A
authors.initials: LA
authors.lastname: Smith
mesh_terms: D000818:Animals; D000992:Antitoxins / Q000737:chemistry / Q000494:pharmacology*; D019274:Botulinum Toxins, Type A / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism*; D045744:Cell Line, Tumor; D002851:Chromatography, High Pressure Liquid; D003014:Clostridium botulinum / Q000378:metabolism*; D016208:Databases, Factual; D005260:Female; D006912:Hydroxyquinolines / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology*; D066298:In Vitro Techniques; D051379:Mice; D015394:Molecular Structure; D010791:Phrenic Nerve / Q000187:drug effects*
chemical_list: D000992:Antitoxins; D006912:Hydroxyquinolines; D019274:Botulinum Toxins, Type A